Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group.
Two double-blind, placebo-controlled, randomised, multicentre, multinational, parallel-group studies were carried out to identify the optimum dose of intranasal sumatriptan for the acute treatment of migraine. Study medication was taken as a single dose through one nostril in the first study, and as a divided dose through two nostrils in the second study. Totals of 245 and 210 patients with a history of migraine were recruited into the one- and two-nostril studies, respectively. In both studies, headache severity had significantly improved at 120 min after doses of 10-40 mg sumatriptan compared to placebo (P < 0.05) and the greatest efficacy rates were obtained with 20 mg sumatriptan. With 20 mg sumatriptan 78% and 74% of patients experienced headache relief in one- and two-nostril studies respectively. Sumatriptan was generally well tolerated, the most frequently reported event being taste disturbance. The results of the two studies are similar and indicate that administering sumatriptan as a divided dose via two nostrils confers no significant advantage over single-nostril administration.
Department of Neurology, University of Turku, Finland.
R
R
Salonen
E
E
Ashford
C
C
Dahlöf
R
R
Dawson
N E
NE
Gilhus
V
V
Lüben
D
D
Noronha
J M
JM
Warter
D000208:Acute Disease; D000281:Administration, Intranasal; D000328:Adult; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006261:Headache / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D009666:Nose / Q000187:drug effects; D018170:Sumatriptan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D018170:Sumatriptan